North America Heartstring Device and Enclosure Device Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

North America Heartstring Device and Enclosure Device Market Segmentation, By Product Type (Enclose Device and Heartstring Device), Application (Coronary Artery Bypass Grafting (CABG), Aortic Anastomosis, Valve Surgery, and Other), Technology Type (Manual, Automated or Semi-Automated, and Others), End-User (Hospitals, Cardiac Surgery Centers, Academic & Research Institutes, and Others), Distribution Channel (Direct Tenders, Distributors & Dealers, Online Procurement Platforms, and Others) - Industry Trends and Forecast to 2032

North America Heartstring Device and Enclosure Device Market Size

• The North America Heartstring Device and Enclosure Device Market size was valued at USD 38.88 million in 2024 and is expected to reach USD 73.58 million by 2032, at a CAGR of 8.4% during the forecast period
• The expansion of the Heartstring and Enclosure Device market is directly propelled by the increasing integration of smart home ecosystems and the widespread digitalization of commercial properties. This evolution is fueling strong demand for sophisticated, interconnected access control solutions.
• Additionally, shifting consumer expectations toward highly secure, intuitive, and seamless technologies are establishing heartstring and enclosure devices as the benchmark for modern access systems, thereby accelerating market-wide adoption and growth.

North America Heartstring Device and Enclosure Device Market Analysis

• Heartstring device and enclosure device refer to specialized components used across medical and technological applications to enhance safety, precision, and system integrity. The Heartstring device is primarily utilized in cardiovascular surgeries to temporarily seal blood vessels during procedures like coronary artery bypass grafting, minimizing the risk of complications such as embolism.
• Enclosure devices function as critical protective housings, safeguarding sensitive components within medical and smart technology systems from environmental hazards and unauthorized access. The synergy between heartstring and enclosure devices is therefore fundamental to ensuring procedural safety, optimizing device performance, and bolstering operational reliability across the healthcare and smart infrastructure sectors.
• U.S. is expected to dominate the North America Heartstring Device and Enclosure Device Market with the largest revenue share of 62.29% in 2025, primarily due to the presence of advanced healthcare infrastructure, high adoption of innovative surgical technologies, and increased investment in cardiac care solutions. Additionally, the region benefits from the presence of key market players, favorable reimbursement policies, and rising prevalence of cardiovascular diseases, all contributing to sustained market growth
• Enclose device segment is expected to dominate the North America Heartstring Device and Enclosure Device Market with a market share of 63.39% in 2025, due to its critical role in facilitating safe, the enclosure device segment minimally invasive cardiac procedures. Its ability to ensure controlled vascular access and reduce procedural complications is driving widespread clinical adoption

Report Scope and North America Heartstring Device and Enclosure Device Market Segmentation  

North America Heartstring Device and Enclosure Device Market Trends

Growth Potential in Emerging Healthcare Regions

• Progress is accelerating through the expansion of healthcare infrastructure and the rising prevalence of cardiovascular disease in emerging regions.
• Device manufacturers are increasingly collaborating with local hospitals and healthcare providers to introduce heartstring and enclosure systems tailored to the specific needs and resource constraints of these markets.
• These partnerships focus on training healthcare professionals, improving procedural workflows, and facilitating access to advanced cardiac surgical technologies.

For instance,

• In June 2024, a study published in Asian Cardiovascular & Thoracic Annals highlighted the significant strides made by the Cardiac Surgery Intersociety Alliance (CSIA) over five years in enhancing cardiac surgical care across emerging regions, including Asia and Africa. The study emphasized the importance of collaborative efforts in training, resource sharing, and capacity building to address the rising burden of cardiovascular diseases in these regions. By focusing on skill development and infrastructure improvement, the CSIA has played a pivotal role in expanding access to advanced cardiac surgical procedures, thereby tapping into the vast growth potential of these emerging healthcare markets
• In March 2022, a study published in the International Journal of Environmental Research and Public Health examined the implementation of telecardiology in rural areas across various countries. The research highlighted that telecardiology platforms, including remote monitoring and virtual consultations, have significantly improved access to cardiovascular care in underserved regions. Hospitals in these areas have partnered with telemedicine providers to train healthcare professionals, integrate digital health tools, and enhance patient outcomes. This collaboration has been crucial in addressing the rising demand for cardiac services in emerging healthcare regions

Emerging healthcare regions are rapidly upgrading their cardiac care capabilities through investments in infrastructure, training of their workforce, and strategic collaborations. These developments are opening significant opportunities for the adoption of advanced surgical tools like heartstring and enclosure devices.

North America Heartstring Device and Enclosure Device Market Dynamics

Driver

Rising Prevalence of Chronic Venous Disorders (CVDS) Globally

• Chronic Venous Disorders (CVDs) — including varicose veins, chronic venous insufficiency, edema, and venous leg ulcers — are costly, debilitating, and typically progressive.
• Compression therapy is the frontline non-surgical treatment recommended by vascular health experts. Because CVDs often require lifelong management, demand for compression garments and devices continues to grow sustainably.
• This escalating demand underscores the need for ongoing innovation in compression technologies, providing more comfortable and effective solutions.

For instance,

• In May 2023, according to the National Center for Biotechnology Information, a scoping review was conducted to assess the prevalence of Chronic Venous Disease (CVD) among healthcare workers. This review, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, analyzed 15 publications. The findings revealed a mean CVD prevalence of 58.5% and a mean varicose vein prevalence of 22.1% among healthcare workers. These figures suggest an elevated prevalence of CVD in this group compared to the general population, highlighting the need for early diagnosis and preventative measures
• Furthermore, increased awareness and early diagnosis are crucial for slowing disease progression and improving patient quality of life. The economic impact of CVDs also underscores the importance of preventative measures and accessible, long-term management strategies. Ultimately, a multi-pronged approach involving lifestyle modifications, early intervention, and advanced compression therapies is essential to mitigate the rising global burden of CVDs

Opportunity

 Advancements in Heart String Device Technology and Usability

• Continuous innovation in off-pump CABG (Coronary Artery Bypass Grafting) systems, often exemplified by advancements like the Heartstring device, is significantly enhancing surgical accessibility and outcomes.
• These innovations focus on several key areas that directly benefit both the surgical team and the patient. Improvements in stabilizers enable a more precise and steady surgical field on the beating heart, which is crucial for delicate anastomoses. Integrated imaging provides surgeons with enhanced visualization, improving accuracy and reducing complications

For instance,

• In October 2024, the National Center for Biotechnology Information highlighted that wearable devices are revolutionizing the management and diagnosis of Cardio vascular Disease (CVD). These cost-effective tools offer continuous, real-time monitoring of vital parameters, addressing limitations of traditional methods. The review discusses advancements in wearable technologies, categorized by galvanic contact, Photoplethysmography (PPG), and Radio Frequency (RF) waves, also emphasizing the role of AI in CVD diagnostics and future device perspectives
• Technological advancements are lowering technical barriers and enhancing the reproducibility of off-pump CABG procedures. These innovations support wider adoption by reducing surgeon training time, procedural risks, and hospital stays—aligning well with healthcare efficiency objectives.
• By investing in R&D that improves usability and reliability, device makers can justify premium pricing and drive wider procurement by healthcare systems

Restraint/Challenge

Growing Preference for Minimally Invasive Cardiac Procedures

• Minimally invasive cardiac interventions are becoming the preferred approach over traditional open-heart surgery due to their alignment with critical clinical goals. Procedures like Off-Pump Coronary Artery Bypass (OPCAB), transcatheter closure of congenital defects, and percutaneous valve repair offer substantial benefits to both patients and healthcare systems.
• These advanced techniques aim to significantly reduce patient trauma by utilizing smaller incisions or catheter-based methods, bypassing the need for a large chest incision. This less invasive approach results in shorter recovery periods, enabling patients to return to their daily lives more quickly with reduced pain and fewer complications.
• Ultimately, the adoption of these minimally invasive procedures also optimizes health system efficiency by potentially reducing hospital stays, lowering the risk of readmissions, and freeing up resources, demonstrating a clear advantage in modern cardiac care.

For instance,

• In December 2024, according to the National Center for Biotechnology Information, a comprehensive review was conducted to evaluate the utilization and outcomes of off-pump coronary artery bypass grafting (OPCAB). The study highlighted several concerns regarding the overuse of OPCAB, particularly in settings where surgeon experience and institutional volume are limited. It was noted that OPCAB is associated with higher rates of incomplete revascularization and inferior graft patency compared to on-pump CABG.

The shift toward minimally invasive cardiac procedures creates a growing market for related device technologies. Manufacturers who focus on compact, integrated, image-guided solutions stand to gain. Continued evidence generation and guideline adoption, coupled with surgeon training and reimbursement realignment, will help establish these procedures as default standards of care globally.

North America Heartstring Device and Enclosure Device Market Scope

The market is segmented into five notable segments which are based on product type, application, technology type, end-user, and distribution channel.

• By Product Type

On the basis of product type, North America Heartstring Device and Enclosure Device Market is segmented into enclose device, and heartstring device. In 2025, the enclosure device segment is expected to dominate with 63.39% market share due to its critical role in facilitating safe, the enclosure device segment minimally invasive cardiac procedures. Its ability to ensure controlled vascular access and reduce procedural complications is driving widespread clinical adoption.

The enclosure device segment is projected to grow at the highest CAGR of 8.6% during the forecast period. This rapid growth is fueled by the increasing adoption of these devices in complex, off-pump cardiac surgeries to improve patient outcomes. Continuous innovation in heartstring technology, leading to enhanced ease of use and greater reliability in creating secure anastomoses, is directly driving its expanding preference among cardiac surgeons.

• By Application

On the basis of application, the North America Heartstring Device and Enclosure Device Market is segmented into Coronary Artery Bypass Grafting (CABG), aortic anastomosis, valve surgery, and other. Coronary Artery Bypass Grafting (CABG) is further segmented into Coronary Artery Bypass Grafting (CABG), aortic anastomosis, valve surgery, and other. In 2025, the Coronary Artery Bypass Grafting (CABG) segment is expected to dominate with 72.68% market share due to the growing burden of coronary artery disease and the increasing preference for off-pump surgical techniques. CABG procedures benefit significantly from heartstring and enclosure devices that enhance safety and reduce operative risks.

The Coronary Artery Bypass Grafting (CABG) segment is anticipated to exhibit the fastest growth, This growth is driven by the rising incidence of Coronary Artery in aging populations and the development of less invasive valve repair and replacement techniques. These advanced procedures demand precise and reliable tools like heartstring devices to ensure secure and effective outcomes, thereby accelerating adoption in this application.

• By Technology Type

On the basis of technology type, the North America Heartstring Device and Enclosure Device Market is segmented into manual, automated or semi-automated, and others. In 2025, the manual segment is expected to dominate with 63.42% market share due to its widespread clinical acceptance, cost-effectiveness, and ease of use in diverse surgical settings. Stapling systems and clip-based closure devices offer reliable performance with minimal training requirements, driving their continued preference

The manual segment is poised to register the highest CAGR. This growth is propelled by the increasing demand for enhanced surgical precision, reduced procedural times, and superior safety outcomes. The integration of automated technologies with robotic-assisted surgical platforms and the drive to minimize human error in complex cardiac procedures are key factors fueling its rapid market expansion.

• By End User

On the basis of end user, the North America Heartstring Device and Enclosure Device Market is segmented into hospitals, cardiac surgery centers, academic & research institutes, and others. In 2025, hospitals segment is expected to dominate with 61.52% market share due to the high volume of cardiac surgeries performed in Tier 1 and Tier 2 facilities and their access to advanced surgical infrastructure. These institutions also benefit from greater funding, skilled personnel, and integration of cutting-edge cardiovascular technologies.

Meanwhile, hospitals are projected to be the fastest-growing segment, with a CAGR of 8.8%. Their growth is attributed to a rising trend of procedural specialization, which allows these centers to achieve higher efficiency, superior patient outcomes, and quicker adoption of niche technologies. As healthcare shifts towards value-based models, these specialized centers are becoming increasingly preferred for complex cardiovascular interventions.

• By Distribution Channel

On the basis of distribution channel, the North America Heartstring Device and Enclosure Device Market is segmented into direct tenders, distributors & dealers, online procurement platforms, and others. In 2025, the direct tenders segment is expected to dominate the market with 45.45% market share due to bulk purchasing by government-sponsored hospitals and large private hospital networks. This channel ensures cost efficiency, streamlined procurement, and faster access to advanced surgical devices.

The direct tenders segment is expected to record the highest CAGR over the forecast period. This trend is a direct result of the increasing digitalization of healthcare supply chains. These platforms offer greater price transparency, enhanced accessibility for a wider range of buyers (including smaller clinics and research institutes), and simplified logistics, making them an increasingly attractive channel for sourcing medical devices.

North America Heartstring Device and Enclosure Device Market Regional Analysis

• North America dominates and expected to dominate the North America Heartstring Device and Enclosure Device Market with the largest revenue share of 35.96% in 2025, primarily due to the presence of advanced healthcare infrastructure, high adoption of innovative surgical technologies, and increased investment in cardiac care solutions.
• Additionally, the region benefits from the presence of key market players, favorable reimbursement policies, and rising prevalence of cardiovascular diseases, all contributing to sustained market growth

U.S. North America Heartstring Device and Enclosure Device Market Insight

The U.S. North America Heartstring Device and Enclosure Device Market captured the largest revenue share of 62.29% within North America in 2025, fueled by advanced healthcare infrastructure, high adoption of minimally invasive cardiac procedures, favorable reimbursement policies, and a strong presence of key medical device manufacturers.

North America Heartstring Device and Enclosure Device Market Share

The heartstring device and enclosure device industry is primarily led by well-established companies, including:

• Peters Surgical (France)
• Getinge (Sweden)
• KARL STORZ (Germany)

Latest Developments in North America Heartstring Device and Enclosure Device Market

• In July 2025, Getinge entered a strategic partnership with Zimmer Biomet to expand their offerings in the Ambulatory Surgical Center (ASC) sector. This collaboration combines Getinge’s OR infrastructure and sterilization solutions with Zimmer Biomet’s surgical technologies, enabling integrated, turnkey solutions for outpatient centers. The partnership enhances Getinge’s market reach, strengthens its ASC positioning, and supports growth in minimally invasive surgical care.
• In July 2024, Getinge announced the opening of its new Experience Center in India as part of its expansion strategy in Asia. This facility offers hands-on demonstrations of advanced surgical, intensive care, and sterile reprocessing solutions. The development enhances Getinge’s customer engagement, training capabilities, and strengthens its presence in a rapidly growing healthcare market.
• In October 2023, Getinge acquired Healthmark Industries Co. Inc. for approximately USD 320 million. Healthmark is a key provider of instrument care and infection control consumables. This acquisition strengthens Getinge’s position in sterile reprocessing, particularly in the U.S., while supporting global expansion of Healthmark’s product offerings.
• In December 2024, Artivion, Inc. received FDA Humanitarian Device Exemption (HDE) approval for its AMDS Hybrid Prosthesis, marking a key regulatory milestone. This allows the early U.S. commercialization of AMDS for treating acute DeBakey Type I aortic dissections with malperfusion—representing roughly 40% of such cases. The device also holds Breakthrough and Humanitarian Use Designation due to its life-saving potential in a rare, high-risk condition. This development strengthens Artivion’s leadership in the structural heart and aortic surgery market, expands its clinical footprint, and paves the way for broader Premarket Approval (PMA) coverage in the future.
• In November 2023, Artivion announced the completion of patient enrollment in its PERSEVERE clinical trial for the AMDS Hybrid Prosthesis, intended for treating acute DeBakey Type I aortic dissections. The 93-patient, U.S.-based study will support a PMA (Premarket Approval) application to the FDA by 2025. This milestone strengthens Artivion’s position in the aortic and structural heart device market, targeting reduced mortality and complications in high-risk aortic surgery cases.

SKU-74532